Although several studies showed that the addition of IFNα to imatinib led to higher rates of molecular response in CML patients [94, 95], others yielded conflicting results [96, 97]. The gene discussed is IFNA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.